{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T18:04:11Z","timestamp":1764698651663,"version":"3.37.3"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2010,4,20]],"date-time":"2010-04-20T00:00:00Z","timestamp":1271721600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1038\/sj.bjc.6605670","type":"journal-article","created":{"date-parts":[[2010,4,20]],"date-time":"2010-04-20T20:03:12Z","timestamp":1271793792000},"page":"1474-1482","source":"Crossref","is-referenced-by-count":19,"title":["Novel pyrrolo-1,5-benzoxazepine compounds display significant activity against resistant chronic myeloid leukaemia cells in vitro, in ex vivo patient samples and in vivo"],"prefix":"10.1038","volume":"102","author":[{"given":"S A","family":"Bright","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A M","family":"McElligott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J W","family":"O'Connell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"O'Connor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Campiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M W","family":"Deininger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Conneally","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Lawler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D C","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D M","family":"Zisterer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,4,20]]},"reference":[{"key":"BF6605670_CR1","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","volume":"8","author":"JF Apperley","year":"2007","unstructured":"Apperley JF (2007a) Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 8: 1018\u20131029","journal-title":"Lancet Oncol"},{"key":"BF6605670_CR2","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/S1470-2045(07)70379-0","volume":"8","author":"JF Apperley","year":"2007","unstructured":"Apperley JF (2007b) Part II: management of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 8: 1116\u20131128","journal-title":"Lancet Oncol"},{"key":"BF6605670_CR3","first-page":"3598","volume":"63","author":"MT Beck","year":"2003","unstructured":"Beck MT, Chen NY, Franek KJ, Chen WY (2003) Experimental therapeutics prolactin antagonist-endostatin fusion protein as a targeted dual-functional therapeutic agent for breast cancer. Cancer Res 63: 3598\u20133604","journal-title":"Cancer Res"},{"key":"BF6605670_CR4","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1002\/cncr.21590","volume":"106","author":"G Borthakur","year":"2006","unstructured":"Borthakur G, Kantarjian H, Daley G, Talpaz M, O\u2019Brien S, Garcia-Manero G, Giles F, Faderl S, Sugrue M, Cortes J (2006) Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy. Cancer 106: 346\u2013352","journal-title":"Cancer"},{"issue":"1","key":"BF6605670_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.bcp.2010.02.019","volume":"80","author":"Sandra A. Bright","year":"2010","unstructured":"Bright SA, Campiani G, Deininger MW, Lawler M, Williams DC, Zisterer DM (2010) Flavopiridol synergistically enhances pyrrolo-1,5-benzoxazepine-induced apoptosis in human chronic myeloid leukaemia cells in a sequence dependent manner. Biochem Pharmacol; doi:10.1016\/j.bcp.2010.02.019","journal-title":"Biochemical Pharmacology"},{"key":"BF6605670_CR6","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.bcp.2008.10.008","volume":"77","author":"SA Bright","year":"2009","unstructured":"Bright SA, Greene LM, Greene TF, Campiani G, Butini S, Brindisi M, Lawler M, Meegan MJ, Williams DC, Zisterer DM (2009) The novel pyrrolo-1,5-benzoxazepine, PBOX-21, potentiates the apoptotic efficacy of STI571 (imatinib mesylate) in human chronic myeloid leukaemia cells. Biochem Pharmacol 77: 310\u2013321","journal-title":"Biochem Pharmacol"},{"key":"BF6605670_CR7","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/nrd839","volume":"1","author":"R Capdeville","year":"2002","unstructured":"Capdeville R, Buchdunger E, Zimmermann J, Matter A (2002) Glivec (STI571, Imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 1: 493\u2013502","journal-title":"Nat Rev Drug Discov"},{"key":"BF6605670_CR8","doi-asserted-by":"publisher","first-page":"10959","DOI":"10.1158\/0008-5472.CAN-06-1216","volume":"66","author":"R Chen","year":"2006","unstructured":"Chen R, Gandhi V, Plunkett W (2006) A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia. Cancer Res 66: 10959\u201310966","journal-title":"Cancer Res"},{"key":"BF6605670_CR9","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","volume":"105","author":"M Deininger","year":"2005","unstructured":"Deininger M, Buchdunger E, Druker B (2005) The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105: 2640\u20132653","journal-title":"Blood"},{"key":"BF6605670_CR10","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1124\/pr.55.3.4","volume":"55","author":"M Deininger","year":"2003","unstructured":"Deininger M, Druker B (2003) Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol Rev 55: 401\u2013423","journal-title":"Pharmacol Rev"},{"key":"BF6605670_CR11","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","volume":"96","author":"M Deininger","year":"2000","unstructured":"Deininger M, Goldman J, Melo J (2000) The molecular biology of chronic myeloid leukemia. Blood 96: 3343\u20133356","journal-title":"Blood"},{"key":"BF6605670_CR12","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1182\/asheducation-2001.1.87","volume":"1","author":"B Druker","year":"2001","unstructured":"Druker B, Sawyers C, Capdeville R, Ford J, Baccarani M, Goldman J (2001) Chronic myelogenous leukemia. Hematology (Am Soc Hematol Educ Program) 1: 87\u2013112","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"key":"BF6605670_CR13","doi-asserted-by":"publisher","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-06-0980","volume":"12","author":"W Fiskus","year":"2006","unstructured":"Fiskus W, Pranpat M, Balasis M, Bali P, Estrella V, Kumaraswamy S, Rao R, Rocha K, Herger B, Lee F, Richon V, Bhalla K (2006a) Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells. Clin Cancer Res 12: 5869\u20135878","journal-title":"Clin Cancer Res"},{"key":"BF6605670_CR14","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1182\/blood-2005-11-4639","volume":"108","author":"W Fiskus","year":"2006","unstructured":"Fiskus W, Pranpat M, Bali P, Balasis M, Kumaraswamy S, Boyapalle S, Rocha K, Wu J, Giles F, Manley PW, Atadja P, Bhalla K (2006b) Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells. Blood 108: 645\u2013652","journal-title":"Blood"},{"key":"BF6605670_CR15","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1182\/blood-2006-05-025049","volume":"109","author":"FJ Giles","year":"2007","unstructured":"Giles FJ, Cortes J, Jones D, Bergstrom D, Kantarjian H, Freedman SJ (2007) MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 109: 500\u2013502","journal-title":"Blood"},{"key":"BF6605670_CR16","first-page":"1357","volume":"14","author":"LM Greene","year":"2005","unstructured":"Greene LM, Fleeton M, Mulligan J, Gowda C, Sheahan BJ, Atkins GJ, Campiani G, Nacci V, Lawler M, Williams DC, Zisterer DM (2005) The pyrrolo-1,5-benzoxazepine, PBOX-6, inhibits the growth of breast cancer cells in vitro independent of estrogen receptor status and inhibits breast tumour growth in vivo. Oncol Rep 14: 1357\u20131363","journal-title":"Oncol Rep"},{"key":"BF6605670_CR17","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1124\/jpet.106.116640","volume":"321","author":"LM Greene","year":"2007","unstructured":"Greene LM, Kelly L, Onnis V, Campiani G, Lawler M, Williams DC, Zisterer DM (2007) STI-571 enhances the apoptotic efficacy of PBOX-6, a novel microtubule targeting agent, in both STI-571- sensitive and -resistant Bcr-Abl-positive human chronic myeloid leukemia cells. J Pharmacol Exp Ther 321: 288\u2013297","journal-title":"J Pharmacol Exp Ther"},{"key":"BF6605670_CR18","doi-asserted-by":"publisher","first-page":"6082","DOI":"10.1128\/MCB.02202-05","volume":"26","author":"IJ Griswold","year":"2006","unstructured":"Griswold IJ, MacPartlin M, Bumm T, Goss VL, O\u2019Hare T, Lee KA, Corbin AS, Stoffregen EP, Smith C, Johnson K, Moseson EM, Wood LJ, Polakiewicz RD, Druker BJ, Deininger MW (2006) Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib. Mol Cell Biol 26: 6082\u20136093","journal-title":"Mol Cell Biol"},{"key":"BF6605670_CR19","doi-asserted-by":"publisher","first-page":"4143","DOI":"10.1182\/blood-2006-09-046839","volume":"109","author":"F Guilhot","year":"2007","unstructured":"Guilhot F, Apperley J, Kim D, Bullorsky E, Baccarani M, Roboz G, Amadori S, de Souza C, Lipton J, Hochhaus A, Heim D, Larson R, Branford S, Muller M, Agarwal P, Gollerkeri A, Talpaz M (2007) Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood 109: 4143\u20134150","journal-title":"Blood"},{"key":"BF6605670_CR20","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1073\/pnas.0408283102","volume":"102","author":"K Gumireddy","year":"2005","unstructured":"Gumireddy K, Baker SJ, Cosenza SC, John P, Kang AD, Robell KA, Reddy MVR, Reddy EP (2005) A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. Proc Natl Acad Sci USA 102: 1992\u20131997","journal-title":"Proc Natl Acad Sci USA"},{"key":"BF6605670_CR21","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1182\/blood-2002-06-1756","volume":"102","author":"WK Hofmann","year":"2003","unstructured":"Hofmann WK, Komor M, Wassmann B, Jones LC, Gschaidmeier H, Hoelzer D, Koeffler HP, Ottmann OG (2003) Presence of the BCR-ABL mutation E255K prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia. Blood 102: 659\u2013661","journal-title":"Blood"},{"key":"BF6605670_CR22","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","volume":"108","author":"T Hughes","year":"2006","unstructured":"Hughes T, Deininger M, Hochhau A, Branford S, Radich J, Kaeda J, Baccarani M, Cortes J, Cross NC, Druker BJ, Gabert J, Grimwade D, Hehlmann R, Kamel-Reid S, Lipton JH, Longtine J, Martinelli G, Saglio G, Soverini S, Stock W, Goldman JM (2006) Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 108: 28\u201337","journal-title":"Blood"},{"key":"BF6605670_CR23","first-page":"3578","volume":"10","author":"W Kelly","year":"2003","unstructured":"Kelly W, Richon V, O\u2019Connor O, Curley T, MacGregor-Curtelli B, Tong W, Klang M, Schwartz L, Richardson S, Rosa E, Drobnjak M, Cordon-Cordo C, Chiao J, Rifkind R, Marks P, Scher H (2003) Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 10: 3578\u20133588","journal-title":"Clin Cancer Res"},{"key":"BF6605670_CR24","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1007\/s00277-003-0690-5","volume":"82","author":"KA Kreuzer","year":"2003","unstructured":"Kreuzer KA, Le Coutre P, Landt O, Na IK, Schwarz M, Schultheis K, Hochhaus A, Dorken B (2003) Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique. Ann Hematol 82: 284\u2013289","journal-title":"Ann Hematol"},{"key":"BF6605670_CR25","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1038\/sj.leu.2400847","volume":"11","author":"F Lacombe","year":"1997","unstructured":"Lacombe F, Durrieu F, Briais A, Dumain P, Belloc F, Bascans E, Reiffers J, Boisseau MR, Bernard P (1997) Flow cytometry CD45 gating for immunophenotyping of acute myeloid leukemia. Leukemia 11: 1878\u20131886","journal-title":"Leukemia"},{"key":"BF6605670_CR26","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood.V96.3.1070","volume":"96","author":"F Mahon","year":"2000","unstructured":"Mahon F, Deininger M, Schultheis B, Chabrol J, Reiffers J, Goldman J, Melo J (2000) Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 96: 1070\u20131079","journal-title":"Blood"},{"key":"BF6605670_CR27","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0022-3565(24)29659-2","volume":"296","author":"MM Mc Gee","year":"2001","unstructured":"Mc Gee MM, Campiani G, Ramunno A, Fattorusso C, Nacci V, Lawler M, Williams DC, Zisterer DM (2001) Pyrrolo-1 5-benzoxazepines induce apoptosis in chronic myelogenous leukemia (CML) cells by bypassing the apoptotic suppressor bcr-abl. J Pharmacol Exp Ther 296: 31\u201340","journal-title":"J Pharmacol Exp Ther"},{"key":"BF6605670_CR28","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1124\/jpet.104.067561","volume":"310","author":"MM Mc Gee","year":"2004","unstructured":"Mc Gee MM, Greene LM, Ledwidge S, Campiani G, Nacci V, Lawler M, Williams DC, Zisterer DM (2004) Selective induction of apoptosis by the pyrrolo-1,5-benzoxazepine 7-[[dimethylcarbamoyl]oxy]-6-(2-naphthyl)pyrrolo-[2,1-d] (1,5)-benzoxazepine (PBOX-6) in leukemia cells occurs via the c-Jun NH2-terminal kinase-dependent phosphorylation and inactivation of Bcl-2 and Bcl-XL. J Pharmacol Exp Ther 310: 1084\u20131095","journal-title":"J Pharmacol Exp Ther"},{"key":"BF6605670_CR29","doi-asserted-by":"publisher","first-page":"8366","DOI":"10.1158\/0008-5472.CAN-09-0131","volume":"69","author":"AM McElligott","year":"2009","unstructured":"McElligott AM, Maginn EN, Greene LM, McGuckin S, Hayat A, Browne PV, Butini S, Campiani G, Catherwood MA, Vandenberghe E, Williams DC, Zisterer DM, Lawler M (2009) The novel tubulin-targeting agent pyrrolo-1,5-benzoxazepine-15 induces apoptosis in poor prognostic subgroups of chronic lymphocytic leukemia. Cancer Res 69: 8366\u20138375","journal-title":"Cancer Res"},{"key":"BF6605670_CR30","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1177\/107327480901600205","volume":"16","author":"KL McFarland","year":"2009","unstructured":"McFarland KL, Wetzstein GA (2009) Chronic myeloid leukemia therapy: focus on second-generation tyrosine kinase inhibitors. Cancer Control 16: 132\u2013140","journal-title":"Cancer Control"},{"key":"BF6605670_CR31","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1124\/mol.105.021204","volume":"70","author":"JM Mulligan","year":"2006","unstructured":"Mulligan JM, Greene LM, Cloonan S, Mc Gee MM, Onnis V, Campiani G, Fattorusso C, Lawler M, Williams DC, Zisterer DM (2006) Identification of tubulin as the molecular target of proapoptotic pyrrolo-1,5-benzoxazepines. Mol Pharmacol 70: 60\u201370","journal-title":"Mol Pharmacol"},{"key":"BF6605670_CR32","first-page":"225","volume":"2","author":"A Nakajima","year":"2003","unstructured":"Nakajima A, Tauchi T, Sumi M, Bishop W, Ohyashiki K (2003) Efficacy of SCH66336, a farnesyl transferase inhibitor, in conjunction with imatinib against BCR-ABL-positive cells. Mol Cancer Ther 2: 225\u2013226","journal-title":"Mol Cancer Ther"},{"unstructured":"Nathwani SM, Butler S, Fayne D, McGovern NN, Sarkadi B, Meegan MJ, Lloyd DG, Campiani G, Lawler M, Williams DC, Zisterer DM (2009) Novel microtubule-targeting agents, pyrrolo-1,5-benzoxazepines, induce apoptosis in multi-drug-resistant cancer cells. Cancer Chemother Pharmacol; doi:10.1007\/s00280-1009-1200-9","key":"BF6605670_CR33"},{"key":"BF6605670_CR34","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1158\/1078-0432.CCR-05-2282","volume":"12","author":"T Nguyen","year":"2006","unstructured":"Nguyen T, Rahmani M, Gao N, Kramer L, Corbin A, Druker B, Dent P, Grant S (2006) Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1\/2 inhibitors in Bcr\/abl+ leukemia cells sensitive and resistant to imatinib mesylate. Clin Cancer Res 12: 2239\u20132247","journal-title":"Clin Cancer Res"},{"key":"BF6605670_CR35","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","volume":"110","author":"T O\u2019Hare","year":"2007","unstructured":"O\u2019Hare T, Eide CA, Deininger MW (2007) Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 110: 2242\u20132249","journal-title":"Blood"},{"key":"BF6605670_CR36","doi-asserted-by":"publisher","first-page":"5507","DOI":"10.1073\/pnas.0800587105","volume":"105","author":"T O\u2019Hare","year":"2008","unstructured":"O\u2019Hare T, Eide CA, Tyner JW, Corbin AS, Wong MJ, Buchanan S, Holme K, Jessen KA, Tang C, Lewis HA, Romero RD, Burley SK, Deininger MW (2008) SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib. Proc Natl Acad Sci USA 105: 5507\u20135512","journal-title":"Proc Natl Acad Sci USA"},{"key":"BF6605670_CR37","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1182\/blood.V97.5.1404","volume":"97","author":"D Peters","year":"2001","unstructured":"Peters D, Hoover R, Gerlach M, Koh E, Zhang H, Choe K, Kirschmeier P, Bishop W, Daley G (2001) Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR\/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia. Blood 97: 1404\u20131412","journal-title":"Blood"},{"key":"BF6605670_CR38","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1517\/14656566.9.6.1029","volume":"9","author":"A Quint\u00e1s-Cardama","year":"2008","unstructured":"Quint\u00e1s-Cardama A, Cortes J (2008a) Homoharringtonine for the treatment of chronic myelogenous leukemia. Expert Opin Pharmacother 9: 1029\u20131037","journal-title":"Expert Opin Pharmacother"},{"key":"BF6605670_CR39","doi-asserted-by":"publisher","first-page":"4392","DOI":"10.1158\/1078-0432.CCR-08-0117","volume":"14","author":"A Quint\u00e1s-Cardama","year":"2008","unstructured":"Quint\u00e1s-Cardama A, Cortes J (2008b) Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia. Clin Cancer Res 14: 4392\u20134399","journal-title":"Clin Cancer Res"},{"key":"BF6605670_CR40","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1038\/nprot.2006.238","volume":"1","author":"C Riccardi","year":"2006","unstructured":"Riccardi C, Nicoletti I (2006) Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat Protoc 1: 1458\u20131461","journal-title":"Nat Protoc"},{"key":"BF6605670_CR41","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1056\/NEJMc035089","volume":"348","author":"C Roche-Lestienne","year":"2003","unstructured":"Roche-Lestienne C, Lai JL, Darre S, Facon T, Preudhomme C (2003) A mutation conferring resistance to imatinib at the time of diagnosis of chronic myelogenous leukemia. N Engl J Med 348: 2265\u20132266","journal-title":"N Engl J Med"},{"key":"BF6605670_CR42","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1182\/blood.V100.3.1014","volume":"100","author":"C Roche-Lestienne","year":"2002","unstructured":"Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, Lai JL, Philippe N, Facon T, Fenaux P, Preudhomme C (2002) Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 100: 1014\u20131018","journal-title":"Blood"},{"key":"BF6605670_CR43","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/1756-9966-28-84","volume":"28","author":"MR Shah","year":"2009","unstructured":"Shah MR, Kriedt CL, Lents NH, Hoyer MK, Jamaluddin N, Klein C, Baldassare J (2009) Direct intra-tumoral injection of zinc-acetate halts tumor growth in a xenograft model of prostate cancer. J Exp Clin Cancer Res 28: 84","journal-title":"J Exp Clin Cancer Res"},{"key":"BF6605670_CR44","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S1535-6108(02)00096-X","volume":"2","author":"NP Shah","year":"2002","unstructured":"Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J, Sawyers CL (2002) Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2: 99\u2013102","journal-title":"Cancer Cell"},{"key":"BF6605670_CR45","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1586\/14737140.8.9.1387","volume":"8","author":"R Tanaka","year":"2008","unstructured":"Tanaka R, Kimura S (2008) Abl tyrosine kinase inhibitors for overriding Bcr-Abl\/T315I: from the second to third generation. Expert Rev Anticancer Ther 8: 1387\u20131398","journal-title":"Expert Rev Anticancer Ther"},{"key":"BF6605670_CR46","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1038\/sj.leu.2403519","volume":"18","author":"E Weisberg","year":"2004","unstructured":"Weisberg E, Catley L, Kujawa J, Atadja P, Remiszewski S, Fuerst P, Cavazza C, Anderson K, Griffin JD (2004) Histone deacetylase inhibitor NVP-LAQ824 has significant activity against myeloid leukemia cells in vitro and in vivo. Leukemia 18: 1951\u20131963","journal-title":"Leukemia"},{"key":"BF6605670_CR47","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1016\/j.juro.2007.05.120","volume":"178","author":"CR Williams","year":"2007","unstructured":"Williams CR, Tabiosa R, Linehana WM, Neckersa L (2007) Intratumor injection of the Hsp90 inhibitor 17AAG decreases tumor growth and induces apoptosis in a prostate cancer xenograft model. J Urol 178: 1528\u20131532","journal-title":"J Urol"},{"key":"BF6605670_CR48","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/j.bbrc.2004.05.113","volume":"319","author":"M Yamamoto","year":"2004","unstructured":"Yamamoto M, Kurosu T, Kakihana K, Mizuchi D, Miura O (2004) The two major imatinib resistance mutations E255K and T315I enhance the activity of BCR\/ABL fusion kinase. Biochem Biophys Res Commun 319: 1272\u20131275","journal-title":"Biochem Biophys Res Commun"},{"key":"BF6605670_CR49","first-page":"188","volume":"62","author":"C Yu","year":"2002","unstructured":"Yu C, Krystal G, Varticovksi L, McKinstry R, Rahmani M, Dent P, Grant S (2002) Pharmacologic mitogen-activated protein\/extracellular signal-regulated kinase kinase\/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr\/Abl-expressing human leukemia cells. Cancer Res 62: 188\u2013199","journal-title":"Cancer Res"},{"key":"BF6605670_CR50","first-page":"2118","volume":"63","author":"C Yu","year":"2003","unstructured":"Yu C, Rahmani M, Almenara J, Subler M, Krystal G, Conrad D, Varticovski L, Dent P, Grant S (2003) Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr\/Abl+ human myeloid leukemia cells. Cancer Res 63: 2118\u20132126","journal-title":"Cancer Res"},{"key":"BF6605670_CR51","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0022-3565(24)39202-X","volume":"293","author":"DM Zisterer","year":"2000","unstructured":"Zisterer DM, Campiani G, Nacci V, Williams DC (2000) Pyrrolo-1,5-benzoxazepines induce apoptosis in HL-60, Jurkat, and Hut-78 cells: a new class of apoptotic agents. J Pharmacol Exp Ther 293: 48\u201359","journal-title":"J Pharmacol Exp Ther"},{"key":"BF6605670_CR52","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1042\/bst0290704","volume":"29","author":"DM Zisterer","year":"2001","unstructured":"Zisterer DM, McGee MM, Campiani G, Ramunno A, Fattorusso C, Nacci V, Lawler M, Williams DC (2001) Pyrrolo-1,5-benzoxazepines: a new class of apoptotic agents. Biochem Soc Trans 29: 704\u2013706","journal-title":"Biochem Soc Trans"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6605670.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6605670","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6605670.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T02:55:02Z","timestamp":1740020102000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6605670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,20]]},"references-count":52,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["BF6605670"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6605670","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"type":"print","value":"0007-0920"},{"type":"electronic","value":"1532-1827"}],"subject":[],"published":{"date-parts":[[2010,4,20]]}}}